Guo Yanshuo, Mao Tianqi, Fang Yafei, Wang Hui, Yu Jiayue, Zhu Yifan, Shen Shige, Zhou Mengze, Li Huanqiu, Hu Qinghua
School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.
J Adv Res. 2025 Mar;69:427-448. doi: 10.1016/j.jare.2024.03.027. Epub 2024 Mar 31.
Purinergic P2 receptors, which can be divided into ionotropic P2X receptors and metabotropic P2Y receptors, mediate cellular signal transduction of purine or pyrimidine nucleoside triphosphates and diphosphate. Based on the wide expression of purinergic P2 receptors in tissues and organs, their significance in homeostatic maintenance, metabolism, nociceptive transmission, and other physiological processes is becoming increasingly evident, suggesting that targeting purinergic P2 receptors to regulate biological functions and signal transmission holds significant promise for disease treatment.
This review highlights the detailed mechanisms by which purinergic P2 receptors engage in physiological and pathological progress, as well as providing prospective strategies for discovering clinical drug candidates.
The purinergic P2 receptors regulate complex signaling and molecular mechanisms in nervous system, digestive system, immune system and as a result, controlling physical health states and disease progression. There has been a significant rise in research and development focused on purinergic P2 receptors, contributing to an increased number of drug candidates in clinical trials. A few influential pioneers have laid the foundation for advancements in the evaluation, development, and of novel purinergic P2 receptors modulators, including agonists, antagonists, pharmaceutical compositions and combination strategies, despite the different scaffolds of these drug candidates. These advancements hold great potential for improving therapeutic outcomes by specifically targeting purinergic P2 receptors.
嘌呤能P2受体可分为离子型P2X受体和代谢型P2Y受体,介导嘌呤或嘧啶核苷三磷酸及二磷酸的细胞信号转导。基于嘌呤能P2受体在组织和器官中的广泛表达,它们在稳态维持、代谢、痛觉传递及其他生理过程中的意义日益明显,这表明靶向嘌呤能P2受体来调节生物学功能和信号传递在疾病治疗方面具有重大前景。
本综述重点阐述嘌呤能P2受体参与生理和病理过程的详细机制,并提供发现临床候选药物的前瞻性策略。
嘌呤能P2受体在神经系统、消化系统、免疫系统中调节复杂的信号和分子机制,从而控制身体健康状态和疾病进展。针对嘌呤能P2受体的研发显著增加,使得临床试验中的候选药物数量增多。尽管这些候选药物的结构不同,但一些有影响力的先驱者为新型嘌呤能P2受体调节剂(包括激动剂、拮抗剂、药物组合物和联合策略)的评估、开发及进展奠定了基础。这些进展通过特异性靶向嘌呤能P2受体改善治疗效果具有巨大潜力。